ETNB - 89bio Inc
89bio Inc Logo

ETNB - 89bio Inc

https://www.89bio.com
Hold Momentum: Bearish
Recent News
Powered by Alpha Vantage
AI Tools
Key Metrics
Trend: Downtrend
As of 2025-09-09 (Snapshot)

89bio, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for the treatment of liver and cardiometabolic diseases. The company is headquartered in San Francisco, California.

52W High
$11.84
52W Low
$4.16
MA Status:
50D: Below 200D: Below
Beta (~1 neutral, <0.9 lower risk)
1.27
Valuation
As of 2025-06-30 (Overview)
Trailing P/E (<15 better)
N/A
Forward P/E (<15 better)
N/A
EV/EBITDA (<8 favorable)
-2.75
EV/Revenue (<3 favorable)
N/A
P/S (TTM) (<3 favorable)
N/A
P/B (<3 favorable)
2.52
Ownership
Institution‑heavy
Source: Overview
Insiders (1–5% typical)
0.54%
Institutions (25–75% balanced)
111.89%
Shares Outstanding
148,308,000
Float
103,725,000
Dividend Yield (2–6% sweet spot)
N/A
Ex‑Dividend Date
N/A
Income & Growth
Profitability: Weak
As of 2025-06-30 (Overview)
Revenue (TTM)
0
Gross Profit (TTM)
0
EPS (TTM)
-3.69
Profit Margin (>10% good)
N/A
Operating Margin (TTM) (higher better)
N/A
ROE (TTM) (>15% strong)
-0.87%
EPS YoY (Quarterly) (>10% good)
N/A
Revenue YoY (Quarterly) (>8% good)
N/A
Momentum
Bearish momentum
Value
-0.3306
Previous
-0.2710
Trend
Falling
Signal Cross
No cross
As of
Sep. 12, 2025